TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07650942: A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Re-randomized Study To Assess the Efficacy and Safety With Hemay005 Tablets in Chinese Patients With Moderately to Severely Active Ulcerative Colitis

Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 360 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07650942 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07650942 Rescue Dossier →